In multiple myeloma, we observed enhanced tumor clearance and mouse survival upon anti-BCMA BAFF-R CAR T cell treatment with low stress-test doses, pointing to the potential for clinical development of BAFF-R-based CARs in multiple myeloma. The gene discussed is TNFRSF13C; the disease is AL amyloidosis.